STERIS Plc (Ireland)

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IE00BFY8C754
USD
261.02
1.62 (0.62%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About STERIS Plc (Ireland) stock-summary
stock-summary
STERIS Plc (Ireland)
Pharmaceuticals & Biotechnology
Steris plc, formerly Steris Ltd, is a provider of infection prevention and other procedural products and services. The Company offers a mix of capital equipment products, such as sterilizers and washers, surgical tables, lights and equipment management systems and connectivity solutions, such as operating room integration; consumable products, such as detergents and gastrointestinal endoscopy accessories and other products; services, including equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair solutions, laboratory services and outsourced reprocessing. The Company operates through four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. It’s Corporate and other segment includes the Defense and Industrial business unit. The Company serves the customers in the United Kingdom, the United States and many other countries throughout the world.
Company Coordinates stock-summary
Company Details
Block a Riverside IV, 70 Sir John Rogerson's Quay DUBLIN None : 2
stock-summary
Tel: 353 1 23220001 440 3927245
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 141 Schemes (39.96%)

Foreign Institutions

Held by 289 Foreign Institutions (34.24%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Mohsen Sohi
Independent Chairman of the Board
Mr. Walter Rosebrough
President, Chief Executive Officer, Director
Mr. Christopher Holland
Director
Mr. Richard Breeden
Independent Director
Ms. Cynthia Feldmann
Independent Director
Dr. Jacqueline Kosecoff
Independent Director
Mr. David Lewis
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,391 Million
(Quarterly Results - Jun 2025)
Net Profit:
178 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 24,457 Million (Mid Cap)

stock-summary
P/E

34.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.94%

stock-summary
Debt Equity

0.24

stock-summary
Return on Equity

10.31%

stock-summary
Price to Book

3.52